177 related articles for article (PubMed ID: 34754394)
1. Immunotherapy after liver transplantation: Where are we now?
Au KP; Chok KSH
World J Gastrointest Surg; 2021 Oct; 13(10):1267-1278. PubMed ID: 34754394
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant Programmed Cell Death 1 (PD-1) Inhibitor Treatment in Patients With Hepatocellular Carcinoma Before Liver Transplant: A Cohort Study and Literature Review.
Qiao ZY; Zhang ZJ; Lv ZC; Tong H; Xi ZF; Wu HX; Chen XS; Xia L; Feng H; Zhang JJ; Xia Q
Front Immunol; 2021; 12():653437. PubMed ID: 34349755
[TBL] [Abstract][Full Text] [Related]
3. Kidney and liver organ transplantation in persons with human immunodeficiency virus: An Evidence-Based Analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2010; 10(4):1-56. PubMed ID: 23074407
[TBL] [Abstract][Full Text] [Related]
4. The Role of Immunotherapy in Hepatocellular Carcinoma: A Systematic Review and Pooled Analysis of 2,402 Patients.
Ziogas IA; Evangeliou AP; Giannis D; Hayat MH; Mylonas KS; Tohme S; Geller DA; Elias N; Goyal L; Tsoulfas G
Oncologist; 2021 Jun; 26(6):e1036-e1049. PubMed ID: 33314549
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant infection improves outcome of hepatocellular carcinoma patients after orthotopic liver transplantation.
Chao JS; Zhao SL; Ou-Yang SW; Qian YB; Liu AQ; Tang HM; Zhong L; Peng ZH; Xu JM; Sun HC
World J Gastroenterol; 2019 Oct; 25(37):5630-5640. PubMed ID: 31602163
[TBL] [Abstract][Full Text] [Related]
6. Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: the Mayo Clinic experience.
DeLeon TT; Salomao MA; Aqel BA; Sonbol MB; Yokoda RT; Ali AH; Moss AA; Mathur AK; Chascsa DM; Rakela J; Bryce AH; Borad MJ
J Gastrointest Oncol; 2018 Dec; 9(6):1054-1062. PubMed ID: 30603124
[TBL] [Abstract][Full Text] [Related]
7. An immune function assay predicts post-transplant recurrence in patients with hepatocellular carcinoma.
Cheng JW; Shi YH; Fan J; Huang XW; Qiu SJ; Xiao YS; Wang Z; Dai Z; Tang ZY; Zhou J
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1445-53. PubMed ID: 21809031
[TBL] [Abstract][Full Text] [Related]
8. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
Zhou J; Fan J; Wang Z; Wu ZQ; Qiu SJ; Huang XW; Yu Y; Sun J; Xiao YS; He YF; Wang YQ; Tang ZY
World J Gastroenterol; 2006 May; 12(19):3114-8. PubMed ID: 16718799
[TBL] [Abstract][Full Text] [Related]
9. When immunotherapy meets liver transplantation for hepatocellular carcinoma: A bumpy but promising road.
Gu Y; Xu S; Wang Z; Yang J; Zheng S; Wei Q; Liu Z; Xu X
Chin J Cancer Res; 2023 Apr; 35(2):92-107. PubMed ID: 37180832
[TBL] [Abstract][Full Text] [Related]
10. Early steroid withdrawal after liver transplantation for hepatocellular carcinoma.
Chen ZS; He F; Zeng FJ; Jiang JP; Du DF; Liu B
World J Gastroenterol; 2007 Oct; 13(39):5273-6. PubMed ID: 17876900
[TBL] [Abstract][Full Text] [Related]
11. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study.
Boucek RJ; Naftel D; Boucek MM; Chinnock R; Morrow RW; Pahl E; DiSano S
J Heart Lung Transplant; 1999 May; 18(5):460-9. PubMed ID: 10363691
[TBL] [Abstract][Full Text] [Related]
12. Immune Checkpoint Inhibitors in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Case Report and Literature Review.
Qiu J; Tang W; Du C
Curr Cancer Drug Targets; 2020; 20(9):720-727. PubMed ID: 32433005
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
14. Impact of immunosuppression and acute rejection on recurrence of hepatitis C: results of the National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database.
Charlton M; Seaberg E
Liver Transpl Surg; 1999 Jul; 5(4 Suppl 1):S107-14. PubMed ID: 10431024
[TBL] [Abstract][Full Text] [Related]
15. Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective.
Ho CM; Chen HL; Hu RH; Lee PH
Ther Adv Med Oncol; 2019; 11():1758835919843463. PubMed ID: 31065295
[TBL] [Abstract][Full Text] [Related]
16. Immunotherapy for hepatocellular carcinoma: the next evolution in expanding access to liver transplantation.
Li M; Bhoori S; Mehta N; Mazzaferro V
J Hepatol; 2024 Jun; ():. PubMed ID: 38848767
[TBL] [Abstract][Full Text] [Related]
17. Advances and effectiveness of the immunotherapy after liver transplantation.
Vulasala SSR; Onteddu NK; Kumar SP; Lall C; Bhosale P; Virarkar MK
World J Gastrointest Surg; 2022 Jun; 14(6):629-631. PubMed ID: 35979423
[TBL] [Abstract][Full Text] [Related]
18. Mammalian target of rapamycin inhibitors are associated with lower rates of hepatocellular carcinoma recurrence after liver transplantation: a systematic review.
Cholongitas E; Mamou C; Rodríguez-Castro KI; Burra P
Transpl Int; 2014 Oct; 27(10):1039-49. PubMed ID: 24943720
[TBL] [Abstract][Full Text] [Related]
19. Predictors of Overall and Progression-Free Survival in Patients with Ocular Melanoma Metastatic to the Liver Undergoing Y90 Radioembolization.
Levey AO; Elsayed M; Lawson DH; Ermentrout RM; Kudchadkar RR; Bercu ZL; Yushak ML; Newsome J; Kokabi N
Cardiovasc Intervent Radiol; 2020 Feb; 43(2):254-263. PubMed ID: 31686137
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of sorafenib in the prevention and treatment of hepatocellular carcinoma recurrences after liver transplantation].
Hu AB; He XS; Tai Q; Zhu XF; Ma Y; Wang DP; Wang GD; Wu LW; Ju WQ; Huang JF
Zhonghua Yi Xue Za Zhi; 2012 May; 92(18):1264-7. PubMed ID: 22883065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
